2020 ASCO Virtual Direct™ Highlights

 

Breast
16:43

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HR+ EBC: Can We De-escalate Adjuvant Chemotherapy Using MammaPrint? What Is the Outcome of Fulvestrant +/- AI vs. AI? Can the new Breast Cancer Index Test Help Identify Patients Who May Benefit from Extended AI Therapy?

FEATURING Cynthia Ma
  • 474 views
  • July 16, 2020
  • 4
10:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ EBC: Is T-DM1 + Pertuzumab Superior in IDFS? Does Anthracycline Add Benefit to TaxolCarboHP Regimen? Is Early PET Response Predicting Higher PCR Rate a Good Strategy for De-escalation?

FEATURING Cynthia Ma
  • 129 views
  • July 13, 2020
05:01

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Early TNBC: Does Metronomic Capecitabine Improve DFS Following Standard Adjuvant Therapy?

FEATURING Cynthia Ma
  • 286 views
  • July 13, 2020
  • 2
11:33

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on ER+ MBC: Fulvestrant vs. Letrozole + Palbociclib in the First-line Setting - Is There an Optimal Endocrine Backbone for CDK4/6? Can Genomic Alterations Help Predict Responsiveness?

FEATURING Jane Meisel
  • 357 views
  • July 16, 2020
  • 2
09:18

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HER2+ MBC: Is Tucatinib the First TKI to Demonstrate Prolongation of OS in Patients With Brain Mets?

FEATURING Jane Meisel
  • 132 views
  • July 13, 2020
  • 1
11:47

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Metastatic TNBC: Are Chemoimmunotherapy Pembro Combinations Helpful in PD-L1+ Disease? Can TMB Help in Patient Selection? What Is the Role of PARPi Beyond BRCA?

FEATURING Jane Meisel
  • 199 views
  • July 13, 2020
  • 1
05:09

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on MBC: Is There a Survival Benefit for Surgery?

FEATURING Jane Meisel
  • 586 views
  • July 13, 2020
  • 2
14:57

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ Curative Setting BC: Who Should Be Considered for Preoperative Systemic Therapy for EBC? Do We Always/Ever Need Anthracyclines? Can We Shorten Trastuzumab Duration?

FEATURING Reshma L. Mahtani
  • 384 views
  • July 13, 2020
  • 2
15:12

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ Curative Setting BC: Pertuzumab to SoC Trastuzumab vs. Utilizing T-DM1 for Pts w/ Residual Disease vs. Extending Adjuvant Tx With 1 yr of Neratinib?

FEATURING Reshma L. Mahtani
  • 330 views
  • July 16, 2020
  • 2
17:22

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2 Targeted Therapy in HER2+ MBC: Efficacy Comparison of Sequencing Newly Approved T-DM1 vs. Neratinib vs. Tucatinib With Existing Therapies

FEATURING Reshma L. Mahtani
  • 342 views
  • July 13, 2020
  • 3